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June 2, 2009:2101–7ortality for hypertensive patients, they did not analyze the
nfluence of baseline heart rate in their meta-analysis, a major
onfounding factor. We performed a similar meta-regression
nalysis in the same set of studies. We first checked that we
btained similar results concerning the influence of heart rate,
easured at the end of the trial in the beta-blocker group, on the
elative risk of myocardial infarction (Fig. 3 of Bangalore et al. [1]):
he equation derived from our analysis (y  2.593 – 0.0237x;
 0.0072) was very close to the equation (y  2.5794 – 0.0235x;
 0.0001) found by Bangalore et al. (1). We further analyzed the
nfluence of heart rate, measured at baseline in the beta-blocker
roup, on the relative risk of myocardial infarction, and found a
ignificant relationship (y  3.864 – 0.0380x; p  0.0001). The
ower the heart rate at baseline, the higher the relative risk of
yocardial infarction. Importantly, the slope of the later equation
baseline heart rate) was 1.6-fold higher (p  0.001) than that of
he former one (heart rate at the end of the trial). These results
uggest that heart rate at baseline (i.e., before any administration of
eta-blocker) is a better predictor of myocardial infarction than
eart rate at the end of the trial. The relative risk for myocardial
nfarction was higher than unity when baseline heart rate was lower
han 75.4 beats/min, and lower than unity when heart rate was
igher than this value.
Thus, heart rate at baseline may have acted as a confounding
actor in the analysis performed by Bangalore et al. (1). This
uggests that reduction in heart rate may not be the main
echanism through which beta-blockers devoid of vasodilating
roperties, particularly atenolol, exert deleterious effects on the
ardiovascular system, and demonstrate less effect than other
ntihypertensive agents for preventing cardiovascular events. In-
eed, in contrast to vasodilating agents like calcium-channel
lockers and renin-angiotensin system blockers, atenolol does not
educe total peripheral resistance and sympathetic drive, and fails
o induce the long-term remodeling of large and small arteries that
s required for structural improvement of arterial stiffness and
esistance and the reduction in wave reflection and central aortic
lood pressure.
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angalore et al. (1) have provided an intriguing observation that
ardiovascular (CV) events, including CV death, myocardial in-
arction, heart failure, stroke, and all-cause death, may be increased
n hypertensive patients placed on beta-blockers and that this may
e related to the degree of heart rate reduction. They have done
his by performing meta-regression analyses to demonstrate the
elationship between heart rate and cardiovascular outcomes.
However, the data in their graphs show that the regression lines
ross the line of unity. The 1 study that is consistently at or below
nity in their graphs is the IPPSH (International Prospective
rimary Prevention Study in Hypertension), which compared a
eta-blocker with placebo. Similarly, the only other placebo-
ontrolled trial analyzed, STOP (Swedish Trial in Old Patients
ith Hypertension) (2), shows a relative risk of about 0.9 in Figure
of Bangalore et al. (1). This suggests that beta-blockers are not
ncreasing CV events because there is no increase in events in
eta-blocker patients compared with placebo patients. The major
ifferences in outcome rates are in the studies comparing beta-
lockers with active controls.
These findings suggest that beta-blockers were less effective at
reventing CV events than other antihypertensive agents. The
echanism for this may be evident in Table 2 of Bangalore et al.
1), which shows that beta-blockers resulted in less blood pressure
eduction in 5 of 7 active control trials analyzed by the authors,
ith up to a 9.2-mm Hg difference in systolic blood pressure. This
uggests that beta-blockers were simply less effective antihyperten-
ive agents in general. Thus, an alternative interpretation of the
uthors’ findings is not that beta-blockers increase mortality, as has
een widely reported in the press, but that beta-blockers are simply
ess effective antihypertensive agents than diuretics or dihydropyr-
dine calcium-channel blockers. As a result, they are also less
ffective at preventing hypertension-related cardiovascular events
han other medications. The clinical message I would take from
his study is that we must remember that the primary goal of
ntihypertensive treatment is to lower blood pressure and not to
ower heart rate.
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ifferent Metabolic Effects of
elective and Nonselective
eta-Blockers Rather Than Mere
eart Rate Reduction May Be
he Mechanisms by Which
eta-Blockade Prevents
ardiovascular Events
e read with interest the article by Bangalore et al. (1), who
nalyzed in 9 trials the role of pharmacologic reduction of heart
ate (HR) using beta-blockers in preventing cardiovascular events
n patients with hypertension. Beta-blocker–induced lower HR
as associated with greater mortality and morbidity risk. As the
asis of worse outcomes with “beta-blockers,” the authors recog-
ize only an increase in central aortic/pulse pressure with pharma-
ologic HR lowering. Even though they acknowledge that the
eta-blocker used in the studies was mainly atenolol, and hence,
ny extrapolation of these results to other beta-blockers should be
one with caution, the whole paper and the accompanying
ditorial just generically refer to “beta-blockade.” In fact, the
echanisms by which beta-blockers improve prognosis in different
ardiac contexts are probably multiple. Improved energy efficiency
een with some beta-blockers (2) could be one of the reasons for
etter survival observed with their use (3). Additionally, central
nhibition of sympathetic activity with moxonidine in heart failure,
espite a significant reduction of HR, has been associated with
ncreased mortality (4). In fact, moxonidine has been shown to
lter myocardial metabolism (5). This could be the reason for the
ailure of central sympathetic inhibition to prevent deaths in
atients with heart failure and also indicates that the predominant
echanism of action of “effective” beta-blockers is probably related
o mechanisms other than mere HR reduction. In fact, apart from
educing HR, atenolol and most selective beta-blockers impair
ndothelial function, decrease insulin sensitivity, and increase lipid
evels (6), all conditions that may worsen the global risk profile.
onversely, new generation beta-blockers have been seen to
mprove metabolism and endothelial function (7). Therefore, HR
eduction in itself, especially if associated with a bulk of deleterious
etabolic and vascular effects, is definitely not enough to improve
rognosis. The alarm created by the Bangalore et al. (1) paper
hould be clearly confined to selective beta-blockers and not
enerically extended to the whole drug class.
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eta-Blockers and Hypertension
angalore et al. (1) state that unlike results from post-myocardial
nfarction and congestive heart failure studies, a beta-blocker–
nduced low heart rate (HR) in hypertension is associated with an
ncrease in death rate and cardiovascular (CV) events. This
onclusion is highly misleading.
In post-myocardial infarction and congestive heart failure studies,
he benefit from beta-1 blockade arises from decreased work of the
eart (via reduced HR and blood pressure), reduced ventricular
brillation risk, and a reduction in catecholamine-induced (beta-1)
ardiac necrosis and apoptosis (2); thus, intrinsic sympathomimetic
ctivity reduces efficacy (2). The situation with hypertension is
omplex, as diastolic hypertension in the young/middle-aged arises
rom a link with obesity (3) and high sympathetic nerve activity plus
aised cardiac output (2). In contrast, isolated systolic hypertension
rises in the elderly via a decrease in vascular compliance (3).
The 3 main contributor trials in the Bangalore et al. (1) study
ere the ASCOT (Anglo-Scandinavian Cardiac Outcomes),
IFE (Losartan Intervention for Endpoint Reduction in Hyper-
ension), and INVEST (International Verapamil SR Trandolapril
tudy) studies in elderly patients with hypertension, which in-
olved moderately beta-1 selective atenolol as the first-line choice.
tenolol does not improve vascular compliance (2), so it does not
ower central systolic pressure; indeed first-line atenolol slightly
ncreases central pressure (4), possibly linked to partial beta-2 block-
